<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">        <PMID Version="1">30197514</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>02</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1178-2013</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>International journal of nanomedicine</Title>                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>            </Journal>            <ArticleTitle>Magnetic nanoparticle hyperthermia potentiates paclitaxel activity in sensitive and resistant breast cancer cells.</ArticleTitle>            <Pagination>                <MedlinePgn>4771-4779</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S171130</ELocationID>            <Abstract>                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Overcoming resistance to antimitotic drugs, such as paclitaxel (PTX), would represent a major advance in breast cancer treatment. PTX induces mitotic block and sensitive cells exit mitosis dying by mitotic catastrophe. Resistant cells remain in block and continue proliferation after drug decay, denoting one of the PTX resistance mechanisms. Mild hyperthermia (HT) triggers mitotic exit of PTX-pretreated cells, overcoming PTX resistance and suggesting HT-forced mitotic exit as a promising strategy to potentiate PTX.</AbstractText>                <AbstractText Label="Methods and results" NlmCategory="UNASSIGNED">Superparamagnetic iron oxide nanoparticles (SPIONs) were used to deliver mild HT at 42°C in PTX-pretreated breast adenocarcinoma MCF-7 cells sensitive and resistant to PTX. To evaluate mechanism of cell death, cells were classified based on nuclear morphology into interphase, mitotic, micronucleated, and apoptotic. The combined PTX→SPION treatment resulted in an increase in the percentage of micronucleated cells, an indication of forced mitotic exit. Importantly, in PTX-resistant cells, the combination therapy using SPION HT helps to overcome resistance by reducing the number of cells relative to the control.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">SPION HT potentiates PTX by significantly reducing cell survival, suggesting potential of combined treatment for future clinical translation.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rivera-Rodriguez</LastName>                    <ForeName>Angelie</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA, carlos.rinaldi@ufl.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chiu-Lam</LastName>                    <ForeName>Andreina</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Engineering, University of Florida, Gainesville, FL, USA, carlos.rinaldi@ufl.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morozov</LastName>                    <ForeName>Viacheslav M</ForeName>                    <Initials>VM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, FL, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>UF Health Cancer Center Gainesville, FL, USA, carlos.rinaldi@ufl.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ishov</LastName>                    <ForeName>Alexander M</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, FL, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>UF Health Cancer Center Gainesville, FL, USA, carlos.rinaldi@ufl.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rinaldi</LastName>                    <ForeName>Carlos</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA, carlos.rinaldi@ufl.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Engineering, University of Florida, Gainesville, FL, USA, carlos.rinaldi@ufl.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>UF Health Cancer Center Gainesville, FL, USA, carlos.rinaldi@ufl.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>R21 CA198820</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Int J Nanomedicine</MedlineTA>            <NlmUniqueID>101263847</NlmUniqueID>            <ISSNLinking>1176-9114</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D058185">Magnetite Nanoparticles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P88XT4IS4D</RegistryNumber>                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Colloid Interface Sci. 2009 Jan 1;329(1):107-13</RefSource>                <PMID Version="1">18930466</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Colloid Interface Sci. 2011 Aug 10;166(1-2):8-23</RefSource>                <PMID Version="1">21601820</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Mol Cell Biol. 2007 May;8(5):379-93</RefSource>                <PMID Version="1">17426725</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Differ. 2008 Jul;15(7):1153-62</RefSource>                <PMID Version="1">18404154</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ACS Nano. 2011 Sep 27;5(9):7124-9</RefSource>                <PMID Version="1">21838221</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2002 Aug;13(8):1173-84</RefSource>                <PMID Version="1">12181239</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Biol Cell. 2014 Sep 15;25(18):2677-81</RefSource>                <PMID Version="1">25213191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochim Biophys Acta. 2008 Apr;1785(2):96-132</RefSource>                <PMID Version="1">18068131</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ACS Nano. 2013 Jun 25;7(6):5091-101</RefSource>                <PMID Version="1">23705969</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Surg Oncol Clin N Am. 2012 Oct;21(4):645-63</RefSource>                <PMID Version="1">23021722</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2011 Jun 23;30(25):2799-809</RefSource>                <PMID Version="1">21339734</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 1999 Oct;35(10):1431-9</RefSource>                <PMID Version="1">10673974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Pharm Des. 2012;18(25):3793-803</RefSource>                <PMID Version="1">22591422</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2012 Jan 15;11(2):310-21</RefSource>                <PMID Version="1">22214763</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2004 Apr;4(4):253-65</RefSource>                <PMID Version="1">15057285</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Magn Magn Mater. 2016 Dec 1;419:267-273</RefSource>                <PMID Version="1">28943706</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ACS Nano. 2017 Feb 28;11(2):2284-2303</RefSource>                <PMID Version="1">28178419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Drug Discov. 2010 Oct;9(10):790-803</RefSource>                <PMID Version="1">20885410</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nanomedicine (Lond). 2013 Oct;8(10):1689-707</RefSource>                <PMID Version="1">24074390</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Treat Options Oncol. 2014 Mar;15(1):27-40</RefSource>                <PMID Version="1">24338278</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Biophys J. 2008 Feb;37(2):223-8</RefSource>                <PMID Version="1">17641885</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Hyperthermia. 2013 Dec;29(8):706-14</RefSource>                <PMID Version="1">24106927</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nanosci Nanotechnol. 2011 May;11(5):4153-7</RefSource>                <PMID Version="1">21780419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Nanomedicine. 2014;9:145-53</RefSource>                <PMID Version="1">24379665</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Hyperthermia. 2008 Sep;24(6):467-74</RefSource>                <PMID Version="1">18608593</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomater Sci. 2015 Feb;3(2):391-400</RefSource>                <PMID Version="1">26218130</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2007 May 15;6(10):1200-4</RefSource>                <PMID Version="1">17471023</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurooncol. 2011 Jun;103(2):317-24</RefSource>                <PMID Version="1">20845061</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Biol. 2006 Jun 20;16(12):1194-200</RefSource>                <PMID Version="1">16782009</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drug Resist Updat. 2001 Oct;4(5):303-13</RefSource>                <PMID Version="1">11991684</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2013 Aug 15;12(16):2598-607</RefSource>                <PMID Version="1">23907120</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Colloid Interface Sci. 2012 Jul 1;377(1):40-50</RefSource>                <PMID Version="1">22513169</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Magn Magn Mater. 2015 Nov 15;394:361-371</RefSource>                <PMID Version="1">26273124</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2008 Nov 03;8:318</RefSource>                <PMID Version="1">18980695</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Nanomedicine. 2012;7:3445-71</RefSource>                <PMID Version="1">22848170</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Phys Med Biol. 2017 May 7;62(9):3483-3500</RefSource>                <PMID Version="1">28032621</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Surg. 2015 Apr;209(4):610-5</RefSource>                <PMID Version="1">25746912</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2008 Feb 15;7(4):484-92</RefSource>                <PMID Version="1">18235235</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2004;9 Suppl 2:24-32</RefSource>                <PMID Version="1">15161988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2012 Sep 15;72(18):4611-5</RefSource>                <PMID Version="1">22987486</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Phys. 2009 May;36(5):1906-12</RefSource>                <PMID Version="1">19544810</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Biol Int. 2000;24(2):61-70</RefSource>                <PMID Version="1">10772764</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006979" MajorTopicYN="Y">Hyperthermia, Induced</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058185" MajorTopicYN="N">Magnetite Nanoparticles</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">chemotherapy</Keyword>            <Keyword MajorTopicYN="N">drug resistance</Keyword>            <Keyword MajorTopicYN="N">hyperthermia</Keyword>            <Keyword MajorTopicYN="N">iron oxide nanoparticles</Keyword>            <Keyword MajorTopicYN="N">taxanes</Keyword>        </KeywordList>        <CoiStatement>Disclosure The authors report no conflicts of interest in this work</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30197514</ArticleId>            <ArticleId IdType="doi">10.2147/IJN.S171130</ArticleId>            <ArticleId IdType="pii">ijn-13-4771</ArticleId>            <ArticleId IdType="pmc">PMC6112810</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>